Radiation Impact on Thromboembolic Events
Completed
- Conditions
- Malignant Neoplasm
- Interventions
- Biological: Biomarkers assays
- Registration Number
- NCT02696447
- Lead Sponsor
- Institut de Cancérologie de la Loire
- Brief Summary
The aim of the present study is to determine the frequency and to identify main risk factors for venous thromboembolism of venous thromboembolic complications in a population of cancer patients treated with a curative intent by ionizing radiation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
- patient with a solid cancer (all locations) treated with radiation therapy and / or brachytherapy as curative intent
- to be 18
Exclusion Criteria
- Patient with metastatic cancer,
- Patients whose follow-up at 6 months is not possible
- Patient receiving an anti-coagulative medication (curative doses)
- Pregnant or breastfeeding women,
- Person under protection of justice or unable to give consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cancer treated by radiotherapy Biomarkers assays Patient with a solid cancer (all locations) treated with radiation therapy and/or brachytherapy as curative intent
- Primary Outcome Measures
Name Time Method Venous Thromboembolism event 6 months All venous thromboembolism, whether symptomatic or discovered incidentally, objectified (CT angiography, lung scintigraphy, venous Doppler) between J1 of radiation treatment, up to 6 months following discontinuation of radiation treatment
- Secondary Outcome Measures
Name Time Method Symptomatic VTE 6 months Symptomatic VTE.
Time of occurrence of VTE 6 months Time of occurrence of VTE
C-reactive protein 6 months Dosage of D-dimer 6 months Complete blood count 6 months
Trial Locations
- Locations (2)
CH de Roanne
🇫🇷Roanne, France
Institut de cancérologie Lucien Neuwirth
🇫🇷Saint-Priest-en-Jarez, France